Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Co.'s pipeline is built on the differentiated therapeutic potential of its primary product candidate, tovinontrine (IMR-687), which is an oral, small molecule inhibitor of phosphodiesterase-9. Tovinontrine is in Phase 2b clinical development for the treatment of sickle cell disease and ß-thalassemia. Co. is also developing IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related factor 2. We show 13 historical shares outstanding datapoints in our coverage of IMRA's shares outstanding history.
Understanding the changing numbers of IMRA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like IMRA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching IMRA by allowing them to research IMRA shares outstanding history
as well as any other stock in our coverage universe. |
Free IMRA Email Alerts:
Video: Shares Outstanding Importance
